In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models-A report from the Pediatric Preclinical Testing Consortium. - Kurmasheva RT; Erickson SW; Earley E; Smith MA; Houghton PJ (Pediatric blood & cancer, 2021)